ABBV Earnings Preview: $2.62 EPS Expected April 29

AbbVie Inc. (ABBV) will report first-quarter earnings on April 29, 2026, after market close. Analysts expect earnings per share of $2.62 and revenue of $14.72 billion. The pharmaceutical giant has beaten EPS estimates in three of its last four quarters, showing consistent execution. However, the current estimate represents a decline from the prior quarter’s $2.71 EPS, signaling potential seasonal softness. With a market cap of $349.1 billion and Meyka AI rating the stock a B+, investors should focus on guidance, pipeline updates, and cash flow trends during this earnings preview.

What Analysts Expect from ABBV Earnings

Wall Street has set clear expectations for AbbVie’s first-quarter earnings report. Analysts project earnings per share of $2.62 and total revenue of $14.72 billion. These estimates reflect modest expectations compared to recent quarters. The EPS forecast is notably lower than the prior quarter’s actual $2.71 result, suggesting analysts anticipate sequential decline.

EPS Estimate Analysis

The $2.62 EPS estimate marks a 3.3% decline from the previous quarter’s $2.71 actual earnings. This sequential drop is typical for pharmaceutical companies experiencing seasonal revenue patterns. However, compared to the year-ago quarter, the estimate shows stability, indicating AbbVie maintains consistent profitability despite market headwinds and patent cliff pressures from HUMIRA biosimilar competition.

Revenue Estimate Breakdown

The $14.72 billion revenue estimate represents a 11.4% decline from the prior quarter’s $16.62 billion. This significant sequential drop reflects typical Q1 seasonality in pharmaceutical sales. Year-over-year comparisons will be crucial to assess whether AbbVie is maintaining market share and growing its newer products like SKYRIZI and RINVOQ to offset HUMIRA revenue erosion.

Consensus Rating and Analyst Sentiment

Analysts maintain a predominantly bullish stance on ABBV, with 19 buy ratings, 8 hold ratings, and zero sell ratings. This 2.4-to-1 buy-to-hold ratio demonstrates confidence in AbbVie’s long-term strategy and pipeline strength. The consensus reflects belief that the company can navigate biosimilar competition and drive growth through newer immunology and oncology products.

Historical Earnings Performance and Beat/Miss Pattern

AbbVie has demonstrated a strong track record of meeting or exceeding analyst expectations in recent quarters. Examining the last four quarters reveals important trends about management execution and guidance accuracy.

Recent Quarter Results

In the most recent quarter (Q4 2025), AbbVie reported $2.71 EPS against a $2.65 estimate, beating by $0.06 or 2.3%. Revenue came in at $16.62 billion versus $16.41 billion estimated, a beat of $207 million. The prior quarter (Q3 2025) showed $1.86 EPS versus $1.77 estimate, beating by $0.09 or 5.1%. Revenue was $15.78 billion against $15.59 billion estimated. This pattern of consistent beats suggests management provides conservative guidance.

Beat/Miss Trend Analysis

AbbVie has beaten EPS estimates in three of the last four quarters, with only one quarter showing a miss. This 75% beat rate is strong for a large-cap pharmaceutical company. Revenue beats occurred in three of four quarters as well. The consistency suggests management has good visibility into demand and execution capabilities, supporting confidence in current quarter estimates.

Prediction for April 29 Earnings

Based on historical patterns, there is a 60-65% probability AbbVie beats the $2.62 EPS estimate. Management’s conservative guidance approach and strong operational execution support this outlook. However, the sequential EPS decline and revenue drop warrant caution. If the company beats estimates but provides weak forward guidance, the stock could face selling pressure despite positive surprises.

Key Metrics and What to Watch

Beyond headline EPS and revenue numbers, investors should focus on specific metrics that reveal AbbVie’s competitive position and growth trajectory.

Product-Level Performance

Watch for revenue breakdowns by therapeutic area. HUMIRA sales will be critical, as biosimilar competition continues eroding this former blockbuster. Investors need to see strong growth from SKYRIZI (psoriasis), RINVOQ (rheumatoid arthritis), and IMBRUVICA (oncology) to offset HUMIRA declines. Management should provide updated market share data and patient uptake metrics for these newer products.

Free Cash Flow and Dividend Sustainability

AbbVie’s dividend yield of 3.41% makes cash flow generation essential. The company generated $10.50 free cash flow per share trailing twelve months. Investors should monitor operating cash flow trends and capital expenditure levels. With a payout ratio of 2.76x, the company relies on strong cash generation to maintain its dividend, making this metric critical for income-focused shareholders.

Guidance and Pipeline Updates

Management guidance for full-year 2026 will be crucial. Any changes to revenue or EPS guidance could signal confidence or concern about market conditions. Additionally, updates on late-stage pipeline programs, particularly in oncology and immunology, will influence long-term growth expectations. Regulatory milestones or clinical trial results could significantly impact the stock’s trajectory.

Meyka AI Grade and Investment Context

Meyka AI rates ABBV with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

What the B+ Grade Means

The B+ rating indicates AbbVie is a solid performer relative to peers and the broader market, but not a top-tier investment. The company scores well on analyst consensus and fundamental metrics, but faces headwinds from valuation and profitability concerns. The stock trades at a P/E ratio of 83.63x, significantly elevated compared to historical averages, reflecting market expectations for future growth.

Valuation Considerations

AbbVie’s price-to-sales ratio of 5.72x and enterprise value-to-sales of 6.76x are elevated for a mature pharmaceutical company. These multiples suggest the market has priced in significant growth expectations. If earnings growth disappoints or guidance weakens, the stock could face multiple compression. Conversely, strong execution and pipeline progress could justify current valuations.

Risk Factors to Monitor

Key risks include HUMIRA revenue declines accelerating faster than expected, pipeline setbacks, regulatory challenges, and macroeconomic pressures on healthcare spending. The company’s high debt levels and negative shareholder equity also warrant attention. However, strong cash generation and market leadership in key therapeutic areas provide downside protection.

Final Thoughts

AbbVie’s April 29 earnings will reveal if the company can sustain its beat streak despite declining revenue and EPS. Key focus areas include immunology and oncology franchise growth to offset HUMIRA biosimilar pressure, free cash flow strength supporting the 3.41% dividend, and 2026 guidance. With conservative estimates and a B+ grade reflecting solid fundamentals but high valuations, strong pipeline execution and market share retention are essential to justify current stock prices.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.